TherapeuticsMD Inc (NYSEMKT:TXMD) has earned an average rating of “Buy” from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $17.50.

A number of equities research analysts have issued reports on TXMD shares. Stifel Nicolaus reissued a “buy” rating and set a $20.00 target price on shares of TherapeuticsMD in a report on Thursday, May 25th. Oppenheimer Holdings, Inc. raised shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating in a report on Tuesday, July 11th. BidaskClub raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a report on Friday, September 8th. Finally, Morgan Stanley started coverage on shares of TherapeuticsMD in a report on Friday, September 8th. They set an “equal weight” rating and a $6.00 target price on the stock.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at

Shares of TherapeuticsMD (NYSEMKT:TXMD) opened at 6.60 on Friday. TherapeuticsMD has a 12 month low of $3.50 and a 12 month high of $8.30. The firm’s market cap is $1.35 billion. The company’s 50-day moving average price is $5.97 and its 200-day moving average price is $5.59.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NYSEMKT:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with's FREE daily email newsletter.